Overview

Anti-Tumor Necrosis Factor Therapy In Patients With Ankylosing Spondylitis

Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
Assessed using (1) Adalimumab(Humira) and NSAIDs (2) Use only Adalimumab(Humira) treatment of ankylosing spondylitis patient safety and efficacy.
Phase:
Phase 2
Details
Lead Sponsor:
Chung Shan Medical University
Treatments:
Adalimumab
Anti-Inflammatory Agents, Non-Steroidal
Etanercept
Golimumab
Sulfasalazine